Bausch Health Companies Inc Financials

BHC

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Financial Profile 54/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Bausch Health Companies Inc has an operating margin of 16.1%, meaning the company retains $16 of operating profit per $100 of revenue. This strong profitability earns a score of 80/100, reflecting efficient cost management and pricing power. This is up from 11.0% the prior year.

Growth

Bausch Health Companies Inc's revenue grew 9.9% year-over-year to $9.6B, a solid pace of expansion. This earns a growth score of 57/100.

Liquidity

Bausch Health Companies Inc's current ratio of 0.86 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 14/100, which could limit financial flexibility.

Cash Flow

Bausch Health Companies Inc converts 13.1% of revenue into free cash flow ($1.3B). This strong cash generation earns a score of 65/100.

Altman Z-Score Distress

0.04

Bausch Health Companies Inc scores 0.04, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.2B) relative to total liabilities ($26.8B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Neutral

5/9

Bausch Health Companies Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

-34.72x

For every $1 of reported earnings, Bausch Health Companies Inc generates $-34.72 in operating cash flow ($1.6B OCF vs -$46.0M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

1.1x

Bausch Health Companies Inc earns $1.1 in operating income for every $1 of interest expense ($1.5B vs $1.4B). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

This page shows Bausch Health Companies Inc (BHC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

$9.6B

YoY+9.9%

5Y CAGR+2.3%

10Y CAGR+1.6%

Bausch Health Companies Inc generated $9.6B in revenue in fiscal year 2024. This represents an increase of 9.9% from the prior year.

EBITDA

$2.8B

YoY+26.3%

5Y CAGR+8.5%

10Y CAGR-2.5%

Bausch Health Companies Inc's EBITDA was $2.8B in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 26.3% from the prior year.

Free Cash Flow

$1.3B

YoY+54.2%

5Y CAGR+0.5%

10Y CAGR-4.6%

Bausch Health Companies Inc generated $1.3B in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 54.2% from the prior year.

Net Income

-$46.0M

YoY+92.2%

Bausch Health Companies Inc reported -$46.0M in net income in fiscal year 2024. This represents an increase of 92.2% from the prior year.

EPS (Diluted)

$-0.13

YoY+92.0%

Bausch Health Companies Inc earned $-0.13 per diluted share (EPS) in fiscal year 2024. This represents an increase of 92.0% from the prior year.

Cash & Debt

$1.2B

YoY+24.7%

5Y CAGR-18.3%

10Y CAGR+13.8%

Bausch Health Companies Inc held $1.2B in cash against $18.9B in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

368M

YoY+0.7%

5Y CAGR+0.8%

10Y CAGR+1.0%

Bausch Health Companies Inc had 368M shares outstanding in fiscal year 2024. This represents an increase of 0.7% from the prior year.

Gross Margin

N/A

Operating Margin

16.1%

YoY+5.1pp

5Y CAGR+18.4pp

10Y CAGR-8.3pp

Bausch Health Companies Inc's operating margin was 16.1% in fiscal year 2024, reflecting core business profitability. This is up 5.1 percentage points from the prior year.

Net Margin

-0.5%

YoY+6.3pp

5Y CAGR+20.3pp

10Y CAGR-11.2pp

Bausch Health Companies Inc's net profit margin was -0.5% in fiscal year 2024, showing the share of revenue converted to profit. This is up 6.3 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$616.0M

YoY+2.0%

5Y CAGR+5.5%

10Y CAGR+9.6%

Bausch Health Companies Inc invested $616.0M in research and development in fiscal year 2024. This represents an increase of 2.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$337.0M

YoY+56.7%

5Y CAGR+4.5%

10Y CAGR+1.4%

Bausch Health Companies Inc invested $337.0M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 56.7% from the prior year.

BHC Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$9.6B+9.9%	$8.8B+7.8%	$8.1B-3.7%	$8.4B+5.1%	$8.0B-6.7%	$8.6B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$616.0M+2.0%	$604.0M+14.2%	$529.0M+13.8%	$465.0M+2.9%	$452.0M-4.0%	$471.0M
SG&A Expenses	$3.3B+13.0%	$2.9B+11.1%	$2.6B0.0%	$2.6B+10.9%	$2.4B-7.3%	$2.6B
Operating Income	$1.5B+60.5%	$963.0M+112.1%	$454.0M+0.9%	$450.0M-33.4%	$676.0M+433.0%	-$203.0M
Interest Expense	$1.4B+4.5%	$1.3B-9.3%	$1.5B+2.7%	$1.4B-7.0%	$1.5B-4.8%	$1.6B
Income Tax	$239.0M+8.1%	$221.0M+166.3%	$83.0M+195.4%	-$87.0M+76.8%	-$375.0M-594.4%	-$54.0M
Net Income	-$46.0M+92.2%	-$592.0M-163.1%	-$225.0M+76.3%	-$948.0M-69.3%	-$560.0M+68.7%	-$1.8B
EPS (Diluted)	$-0.13+92.0%	$-1.62-161.3%	$-0.62+76.5%	$-2.64-67.1%	$-1.58+68.9%	$-5.08

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$2.7B+6.0%	$2.5B+12.0%	$2.3B-11.7%	$2.6B+6.5%	$2.4B+11.6%	$2.2B-10.6%	$2.4B+7.6%	$2.2B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$166.0M+4.4%	$159.0M+11.2%	$143.0M-12.3%	$163.0M+4.5%	$156.0M+3.3%	$151.0M-0.7%	$152.0M-0.7%	$153.0M
SG&A Expenses	$795.0M-11.1%	$894.0M+3.1%	$867.0M+5.7%	$820.0M-1.4%	$832.0M+4.8%	$794.0M+3.7%	$766.0M+7.1%	$715.0M
Operating Income	$619.0M+39.4%	$444.0M+60.9%	$276.0M-50.5%	$558.0M+43.4%	$389.0M+38.4%	$281.0M-22.4%	$362.0M+2485.7%	$14.0M
Interest Expense	$412.0M-11.4%	$465.0M+40.9%	$330.0M-2.1%	$337.0M-3.7%	$350.0M-1.4%	$355.0M-2.2%	$363.0M+7.1%	$339.0M
Income Tax	$37.0M+208.3%	$12.0M-69.2%	$39.0M-64.9%	$111.0M+126.5%	$49.0M+512.5%	$8.0M-80.0%	$40.0M-28.6%	$56.0M
Net Income	$179.0M+20.9%	$148.0M+355.2%	-$58.0M-162.4%	$93.0M+830.0%	$10.0M+115.6%	-$64.0M-64.1%	-$39.0M+89.7%	-$378.0M
EPS (Diluted)	$0.48+20.0%	$0.40+350.0%	$-0.16-166.7%	$0.24+700.0%	$0.03+117.6%	$-0.17-54.5%	$-0.11+89.3%	$-1.03

BHC Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$26.5B-3.0%	$27.4B+6.5%	$25.7B-12.0%	$29.2B-6.4%	$31.2B-7.9%	$33.9B
Current Assets	$5.8B+3.2%	$5.6B+31.8%	$4.2B-24.3%	$5.6B+5.0%	$5.3B-23.3%	$7.0B
Cash & Equivalents	$1.2B+24.7%	$947.0M+67.9%	$564.0M-3.1%	$582.0M-3.8%	$605.0M-81.3%	$3.2B
Inventory	$1.6B+3.3%	$1.5B+41.7%	$1.1B+9.8%	$993.0M-9.2%	$1.1B-1.2%	$1.1B
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$11.1B-0.9%	$11.2B-3.2%	$11.5B-7.3%	$12.5B-4.5%	$13.0B-0.6%	$13.1B
Total Liabilities	$26.8B-2.1%	$27.4B+7.9%	$25.4B-13.0%	$29.2B-4.4%	$30.6B-6.5%	$32.7B
Current Liabilities	$6.8B+57.0%	$4.3B+9.2%	$3.9B-24.2%	$5.2B+5.8%	$4.9B-21.4%	$6.2B
Long-Term Debt	$18.9B-13.7%	$21.9B+7.9%	$20.3B-10.2%	$22.7B-5.3%	$23.9B-3.0%	$24.7B
Total Equity	-$1.3B-25.1%	-$1.0B-47.7%	-$692.0M-552.8%	-$106.0M-119.8%	$535.0M-49.7%	$1.1B
Retained Earnings	-$9.8B-0.5%	-$9.8B-6.4%	-$9.2B-2.5%	-$9.0B-11.8%	-$8.0B-7.5%	-$7.5B

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$26.8B-1.6%	$27.3B+3.2%	$26.4B-0.4%	$26.5B+0.1%	$26.5B-1.6%	$26.9B-1.6%	$27.4B+1.1%	$27.1B
Current Assets	$6.2B-4.1%	$6.5B+13.6%	$5.7B-0.7%	$5.8B+10.8%	$5.2B-3.4%	$5.4B-3.6%	$5.6B+10.9%	$5.0B
Cash & Equivalents	$1.3B-24.3%	$1.7B+52.3%	$1.1B-4.0%	$1.2B+98.5%	$595.0M-18.8%	$733.0M-22.6%	$947.0M+24.6%	$760.0M
Inventory	$1.6B-3.4%	$1.7B+2.6%	$1.6B+1.1%	$1.6B-1.1%	$1.6B-1.5%	$1.6B+6.0%	$1.5B+21.4%	$1.3B
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$11.3B-0.1%	$11.3B+1.3%	$11.2B+0.6%	$11.1B-0.4%	$11.1B-0.3%	$11.2B-0.2%	$11.2B0.0%	$11.2B
Total Liabilities	$26.5B-2.4%	$27.1B+1.7%	$26.7B-0.7%	$26.8B+0.5%	$26.7B-1.3%	$27.1B-1.3%	$27.4B+0.5%	$27.3B
Current Liabilities	$4.8B-3.7%	$5.0B+16.9%	$4.3B-37.0%	$6.8B+54.5%	$4.4B-0.8%	$4.4B+2.4%	$4.3B+1.8%	$4.2B
Long-Term Debt	$20.5B-1.9%	$20.9B-1.7%	$21.2B+12.1%	$18.9B-10.7%	$21.2B-1.5%	$21.5B-1.8%	$21.9B+0.2%	$21.9B
Total Equity	-$565.0M+26.0%	-$764.0M+35.4%	-$1.2B+7.5%	-$1.3B-8.9%	-$1.2B-5.4%	-$1.1B-9.1%	-$1.0B+13.4%	-$1.2B
Retained Earnings	-$9.6B+1.8%	-$9.7B+1.5%	-$9.9B-0.6%	-$9.8B+0.1%	-$9.8B+0.1%	-$9.8B-0.7%	-$9.8B-0.4%	-$9.7B

BHC Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	$1.6B+54.7%	$1.0B+241.8%	-$728.0M-151.1%	$1.4B+28.4%	$1.1B-26.0%	$1.5B
Capital Expenditures	$337.0M+56.7%	$215.0M-1.4%	$218.0M-19.0%	$269.0M-10.9%	$302.0M+11.9%	$270.0M
Free Cash Flow	$1.3B+54.2%	$817.0M+186.4%	-$946.0M-181.8%	$1.2B+43.0%	$809.0M-34.3%	$1.2B
Investing Cash Flow	-$454.0M+78.8%	-$2.1B-607.9%	-$303.0M-174.1%	$409.0M+256.7%	-$261.0M+37.7%	-$419.0M
Financing Cash Flow	-$868.0M-158.8%	$1.5B+411.2%	-$474.0M+68.7%	-$1.5B+34.0%	-$2.3B-259.0%	$1.4B
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	$405.0M+40.1%	$289.0M+37.0%	$211.0M-64.9%	$601.0M+58.2%	$380.0M+80.1%	$211.0M-45.9%	$390.0M+38.3%	$282.0M
Capital Expenditures	$91.0M-8.1%	$99.0M-13.9%	$115.0M+8.5%	$106.0M+35.9%	$78.0M-4.9%	$82.0M-16.3%	$98.0M+133.3%	$42.0M
Free Cash Flow	$314.0M+65.3%	$190.0M+97.9%	$96.0M-80.6%	$495.0M+63.9%	$302.0M+134.1%	$129.0M-55.8%	$292.0M+21.7%	$240.0M
Investing Cash Flow	-$83.0M+17.0%	-$100.0M+23.1%	-$130.0M+35.0%	-$200.0M-153.2%	-$79.0M-8.2%	-$73.0M+50.7%	-$148.0M+92.2%	-$1.9B
Financing Cash Flow	-$719.0M-300.8%	$358.0M+345.2%	-$146.0M-271.8%	$85.0M+120.0%	-$424.0M-24.7%	-$340.0M-330.4%	-$79.0M-104.4%	$1.8B
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BHC Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	16.1%+5.1pp	11.0%+5.4pp	5.6%+0.2pp	5.3%-3.1pp	8.4%+10.8pp	-2.4%
Net Margin	-0.5%+6.3pp	-6.8%-4.0pp	-2.8%+8.5pp	-11.2%-4.3pp	-7.0%+13.8pp	-20.8%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-0.2%+2.0pp	-2.2%-1.3pp	-0.9%+2.4pp	-3.3%-1.5pp	-1.8%+3.5pp	-5.3%
Current Ratio	0.86-0.4	1.30+0.2	1.080.0	1.080.0	1.09-0.0	1.12
Debt-to-Equity	-14.81+6.7	-21.47+7.9	-29.38+184.3	-213.72-258.4	44.72+21.5	23.20
FCF Margin	13.1%+3.8pp	9.3%+21.0pp	-11.6%-25.4pp	13.7%+3.6pp	10.1%-4.2pp	14.3%

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	23.1%+5.5pp	17.5%+5.3pp	12.2%-9.6pp	21.8%+5.6pp	16.2%+3.1pp	13.1%-2.0pp	15.0%+14.4pp	0.6%
Net Margin	6.7%+0.8pp	5.9%+8.4pp	-2.6%-6.2pp	3.6%+3.2pp	0.4%+3.4pp	-3.0%-1.4pp	-1.6%+15.3pp	-16.9%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	0.7%+0.1pp	0.5%+0.8pp	-0.2%-0.6pp	0.4%+0.3pp	0.0%+0.3pp	-0.2%-0.1pp	-0.1%+1.3pp	-1.4%
Current Ratio	1.300.0	1.31-0.0	1.35+0.5	0.86-0.3	1.19-0.0	1.23-0.1	1.30+0.1	1.20
Debt-to-Equity	-36.22-8.9	-27.30-9.4	-17.94-3.1	-14.81+3.2	-18.05+1.3	-19.31+2.2	-21.47-2.9	-18.55
FCF Margin	11.7%+4.2pp	7.5%+3.3pp	4.3%-15.1pp	19.3%+6.8pp	12.6%+6.6pp	6.0%-6.1pp	12.1%+1.4pp	10.7%

Note: Shareholder equity is negative (-$1.3B), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.86), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Indivior Pharmaceuticals Inc INDV

$4.2B

Hutchmed (China) Limited HCM

$2.5B

Supernus Pharma SUPN

$2.9B

Alvotech ALVO

$1.5B

Amneal Pharmaceuticals Inc AMRX

$4.6B

Frequently Asked Questions

What is Bausch Health Companies Inc's annual revenue?

Bausch Health Companies Inc (BHC) reported $9.6B in total revenue for fiscal year 2024. This represents a 9.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bausch Health Companies Inc's revenue growing?

Bausch Health Companies Inc (BHC) revenue grew by 9.9% year-over-year, from $8.8B to $9.6B in fiscal year 2024.

Is Bausch Health Companies Inc profitable?

No, Bausch Health Companies Inc (BHC) reported a net income of -$46.0M in fiscal year 2024, with a net profit margin of -0.5%.

What is Bausch Health Companies Inc's earnings per share (EPS)?

Bausch Health Companies Inc (BHC) reported diluted earnings per share of $-0.13 for fiscal year 2024. This represents a 92.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Bausch Health Companies Inc's EBITDA?

Bausch Health Companies Inc (BHC) had EBITDA of $2.8B in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Bausch Health Companies Inc have?

As of fiscal year 2024, Bausch Health Companies Inc (BHC) had $1.2B in cash and equivalents against $18.9B in long-term debt.

What is Bausch Health Companies Inc's operating margin?

Bausch Health Companies Inc (BHC) had an operating margin of 16.1% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Bausch Health Companies Inc's net profit margin?

Bausch Health Companies Inc (BHC) had a net profit margin of -0.5% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Bausch Health Companies Inc's free cash flow?

Bausch Health Companies Inc (BHC) generated $1.3B in free cash flow during fiscal year 2024. This represents a 54.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bausch Health Companies Inc's operating cash flow?

Bausch Health Companies Inc (BHC) generated $1.6B in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Bausch Health Companies Inc's total assets?

Bausch Health Companies Inc (BHC) had $26.5B in total assets as of fiscal year 2024, including both current and long-term assets.

What are Bausch Health Companies Inc's capital expenditures?

Bausch Health Companies Inc (BHC) invested $337.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Bausch Health Companies Inc spend on research and development?

Bausch Health Companies Inc (BHC) invested $616.0M in research and development during fiscal year 2024.

How many shares does Bausch Health Companies Inc have outstanding?

Bausch Health Companies Inc (BHC) had 368M shares outstanding as of fiscal year 2024.

What is Bausch Health Companies Inc's current ratio?

Bausch Health Companies Inc (BHC) had a current ratio of 0.86 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Bausch Health Companies Inc's debt-to-equity ratio?

Bausch Health Companies Inc (BHC) had a debt-to-equity ratio of -14.81 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bausch Health Companies Inc's return on assets (ROA)?

Bausch Health Companies Inc (BHC) had a return on assets of -0.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Why is Bausch Health Companies Inc's debt-to-equity ratio negative or unusual?

Bausch Health Companies Inc (BHC) has negative shareholder equity of -$1.3B as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Bausch Health Companies Inc's Altman Z-Score?

Bausch Health Companies Inc (BHC) has an Altman Z-Score of 0.04, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Bausch Health Companies Inc's Piotroski F-Score?

Bausch Health Companies Inc (BHC) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bausch Health Companies Inc's earnings high quality?

Bausch Health Companies Inc (BHC) has an earnings quality ratio of -34.72x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Bausch Health Companies Inc cover its interest payments?

Bausch Health Companies Inc (BHC) has an interest coverage ratio of 1.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Bausch Health Companies Inc?

Bausch Health Companies Inc (BHC) scores 54 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.